Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Listen up! Netflix is officially diving into the podcast biz: The video-streaming giant inked a deal with Spotify to bring a batch of top original podcasts, including from Bill Simmons’ The Ringer, to ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

At a recent JPMorgan Chase employee town hall meeting, one brave soul brought up a petition pushing back against the firm’s decision to force workers to return to the office five days a week. “Don’t ...

Results of thioflavin T fluorescence analyses revealed a drastic increase in the fluorescence intensity when BSA was mixed with ultra-small (10 nm) silica nanoparticles (NPs) with a stirring time of ...

Far-Flung Postcards is a weekly series in which NPR's international team shares snapshots of moments from their lives and work around the world. You might not realize it, but everything from AI ...

Forbes contributors publish independent expert analyses and insights. I track enterprise software application development & data management. Information, without order, is chaotic. Attempting to work ...

PCB Clarifies Selection Committee Structure originally appeared on Athlon Sports. The PCB has put an end to rumors that the current selection committee would undergo significant changes, as four of ...

The Trump administration has expanded Palantir’s work with the government, spreading the company’s technology — which could easily merge data on Americans — throughout agencies. Alex Karp, a ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While growth of data centers ...